TNX-650
Encyclopedia
TNX-650 is a medication for refractory Hodgkin's lymphoma
under development by Tanox
. , a phase 1/2 clinical trial
is recruiting participants.
It is a monoclonal antibody which blocks interleukin 13
.
Hodgkin's lymphoma
Hodgkin's lymphoma, previously known as Hodgkin's disease, is a type of lymphoma, which is a cancer originating from white blood cells called lymphocytes...
under development by Tanox
Tanox
Tanox was a biopharmaceutical company based in Houston, Texas. The company was founded by two biomedical research scientists, Nancy T. Chang and Tse Wen Chang in March 1986. Nancy was the President and CEO of the company in its 21 year history, while Tse Wen was responsible for creating most of the...
. , a phase 1/2 clinical trial
Clinical trial
Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for health interventions...
is recruiting participants.
It is a monoclonal antibody which blocks interleukin 13
Interleukin 13
Interleukin 13 is a protein that in humans is encoded by the IL13 gene. IL-13 is cytokine secreted by many cell types, but especially T helper type 2 cells, that is a mediator of allergic inflammation and disease.-Functions:...
.